Geen categorie

11 januari 2021

Health~Holland public-private-partnership grant award of 0.9 M€

ROTTERDAM, The Netherlands, January 11, 2021 – The partnership between the young company Pan Cancer T B.V. and Erasmus MC is awarded a Health~Holland grant of […]
18 januari 2023

Pan Cancer T Appoints Dr. Rachel Abbott as Chief Scientific Officer

– Strengthening of T cell research expertise to develop next-generation T cell therapies for patients with limited or no treatment options  ROTTERDAM, January 17, 2023 – […]
30 maart 2021

Pan Cancer T B.V. Appoints Seasoned Entrepreneurs and Executives to its Supervisory Board and Elects its Chairman

– John Tchelingerian, PhD (Chair), Dharminder Singh Chahal and Prof. Dr. Chris Bangma to form Supervisory Board ROTTERDAM, March 30, 2021 – Pan Cancer T B.V., […]
27 september 2021

Pan Cancer T celebrates 1-year anniversary!

Pan Cancer T B-day_2021 (2)
28 oktober 2021

Pan Cancer T Extends Seed Financing Round with Additional Funding from Existing Shareholders and New Investor Thuja Capital

Expanded investor syndicate strengthens the company’s financial position and investor base   ROTTERDAM, October 28, 2021 – Pan Cancer T B.V., a biotech spin-off from the […]
15 april 2021

Pan Cancer T is awarded with Axon Innovation for Health Award 2021

Pan Cancer T is awarded with Axon Innovation for Health Award 2021 – selected as the winner out of 21 start-up companies Hilversum, 15 April 2021 […]
7 februari 2021

Press Release: Onco-immunology Company Pan Cancer T Launched as Spin-off from Erasmus Medical Center

Life-saving TCR T-cell therapies for hard-to-treat solid tumors – Dutch biotech company developing first-in-class T-cell Receptor (TCR) T-cell therapies – Seed investment by Swanbridge Capital and […]
1 september 2021

TCR T cells towards solid tumors: perspective on pitfalls and opportunities

TCR T cells towards solid tumors: perspective on pitfalls and opportunities Reno Debets, founder and CSO, PCT BV, Rotterdam, the Netherlands   Rationale Adoptive T cell […]